PegIFN Improves Responses to Dasatinib in Newly Diagnosed CML Patients

News | May 03, 2016 

The addition of pegylated interferon-ɑ2b (PegIFN) to the tyrosine kinase inhibitor (TKI) dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukaemia (CML) patients.

“IFN is a good candidate to further increase the efficacy of TKI treatment, as its mode of action, induction of anti-tumour immunity, and effects on stem cell proliferation and renewal, differs from TKIs,” wrote study authors led by Henrik Hjorth-Hansen, MD, PhD, of the Norwegian University of Science and Technology in Trondheim, Norway.

The study included 40 newly diagnosed CML patients. All began by receiving dasatinib for 3 months, followed by the addition of PegIFN at that point. Dosing of PegIFN began at 15 μg/week and increased to 25 μg/week over the first 3 months. The results of the trial were published in Leukemia.

Full article here:

http://www.cancernetwork.com/chronic-myeloid-leukemia/pegifn-improves-responses-dasatinib-newly-diagnosed-cml-patients?GUID=973F492C-B60B-476A-9B20-E1B81DF4EDE9&XGUID=&rememberme=1&ts=20052016

Published Abstract here:

http://www.nature.com/leu/journal/vaop/naam/abs/leu2016121a.html